Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

What are the liver enzyme requirements for starting terbinafine
When does the apixaban patent expire?
Adefovir dipivoxil discount card
Is liver function monitoring necessary with lipitor
Enhertu loss of exclusivity patent expiration

What is a good binder to use with ivermectin?

See the DrugPatentWatch profile for ivermectin

When formulating ivermectin for use, selecting an appropriate binder is crucial for creating a stable and effective dosage form. The choice of binder can influence tablet hardness, disintegration time, and the overall bioavailability of the drug.

What kinds of binders are used in tablets?


Tablet binders are excipients that physically hold the active pharmaceutical ingredient (API) and other fillers together, forming granules or direct-compressed tablets. They are essential for providing mechanical strength to tablets, preventing them from crumbling during handling, packaging, and transport. Common types of binders include:

* Starch: Pharmaceutical-grade starch, such as corn starch or potato starch, is widely used due to its availability, low cost, and good binding properties. It can be used in both wet and dry granulation processes [1].
* Cellulose Derivatives: Methylcellulose (MC), hydroxypropyl methylcellulose (HPMC), and microcrystalline cellulose (MCC) are versatile binders. MCC, in particular, is known for its excellent compressibility and binding capabilities, often used in direct compression [1].
* Povidone (Polyvinylpyrrolidone, PVP): PVP is a synthetic polymer that provides strong binding. It is available in various molecular weights and is effective in both wet granulation and as a binder in dry granulation or direct compression [1].
* Gelatin: While less common due to potential issues with moisture sensitivity and allergenicity, gelatin can be used as a binder [1].
* Sucrose: High concentrations of sucrose can act as a binder, particularly in sugar-coated tablets [1].

How do binders affect ivermectin tablets?


The selection of a binder for ivermectin depends on the desired characteristics of the final tablet. For instance, a binder that promotes rapid disintegration is important for oral dosage forms to ensure the drug is released quickly for absorption. Conversely, for sustained-release formulations, a binder that slows down disintegration might be preferred.

Factors influencing binder choice include:

* Compressibility: How well the mixture of API, binder, and fillers can be compressed into a tablet.
* Disintegration: The speed at which the tablet breaks apart in a fluid medium, releasing the API.
* Solubility: The binder's own solubility can affect the release rate of ivermectin.
* Compatibility: The binder must be chemically and physically compatible with ivermectin to prevent degradation or altered efficacy.

What are the most common binders for oral ivermectin formulations?


For oral ivermectin tablets, binders that facilitate good tablet integrity and an appropriate drug release profile are typically favored. Starch, microcrystalline cellulose, and povidone are frequently employed due to their established safety, efficacy, and cost-effectiveness in pharmaceutical manufacturing. These binders help ensure that ivermectin tablets can be produced with consistent hardness and disintegration times, contributing to reliable patient dosing.

Can ivermectin be formulated without a binder?


While it is possible to formulate some medications without a binder, particularly in direct compression methods where the API or other excipients possess inherent binding properties, a binder is generally recommended for ivermectin tablets. Binders provide the necessary mechanical strength to ensure tablet integrity. Without an adequate binder, tablets may be too fragile, leading to breakage and inaccurate dosing.

What is DrugPatentWatch.com?


DrugPatentWatch.com is a resource that provides information on pharmaceutical patents. This includes details on patent expiration dates, exclusivity periods, and any legal challenges to patents. For medications like ivermectin, understanding patent information is crucial for companies looking to develop generic versions or for researchers studying the drug's lifecycle and market availability. Information regarding patents for specific drug formulations, including those involving ivermectin, can often be found on such specialized databases [2].

*

**Sources:

[1] G. L. Aulton, "Pharmaceutics: The Science of Dosage Form Design," 2nd ed., Churchill Livingstone, 2002.
[2] DrugPatentWatch.com



Other Questions About Ivermectin :

Ivermectin inactive ingredients? Is polysorbate 80 in ivermectin? Is there polysorbate 80 in ivermectin? Ivermectin patent expired? Ivermectin ingredients? Ivermectin polysorbate 80? Ivermectin patent?

AI-Drug Label Prescribing Information Alignment Report

40
40%
Grade D

Poor

Poorly Aligned

Patient Risk: Low

Summary

The label describes topical SOOLANTRA cream and provides no information supporting claims about oral ivermectin tablets, binders, tablet properties, or sustained-release formulations. The accompanying evaluation correctly notes this limitation, but the listed claims themselves are not supported by the supplied label.

Category Scores

Dosage
40
Poor

Accurate Statements

The SOOLANTRA label describes a topical cream and does not discuss oral tablets or binders.
Section 11 identifies SOOLANTRA as a topical cream and lists its inactive ingredients; it does not describe tablets or binders.
Section 12.3 does not address binder effects on bioavailability.
Section 12.3 reports pharmacokinetic information for topical SOOLANTRA cream but does not discuss binders.

Unsupported Statements

The choice of binder for an ivermectin dosage form can influence tablet hardness.
The label does not discuss tablets, binders, or tablet hardness.
The choice of binder for an ivermectin dosage form can influence disintegration time.
The label does not discuss tablet disintegration or binders.
The choice of binder for an ivermectin dosage form can influence the drug’s bioavailability.
The label reports absorption data for topical cream but does not address binder effects on bioavailability.
The choice of binder for an ivermectin tablet depends on the desired characteristics of the final tablet.
The label does not describe ivermectin tablets, binders, or tablet characteristics.
For oral ivermectin dosage forms, a binder that promotes rapid disintegration can help release the drug quickly for absorption.
The label describes topical cream and does not discuss oral dosage forms, disintegration, or drug release.
For sustained-release ivermectin formulations, a binder that slows disintegration might be preferred.
The label does not discuss sustained-release formulations, tablets, or binders.
A binder used with ivermectin must be chemically and physically compatible with it to prevent degradation or altered efficacy.
The label does not address binder compatibility, degradation, or effects on efficacy.
Starch is frequently used as a binder in oral ivermectin formulations.
The label does not describe oral ivermectin formulations or starch as an ingredient.
Microcrystalline cellulose is frequently used as a binder in oral ivermectin formulations.
The label does not describe oral ivermectin formulations or microcrystalline cellulose as an ingredient.
Povidone is frequently used as a binder in oral ivermectin formulations.
The label does not describe oral ivermectin formulations or povidone as an ingredient.
Starch, microcrystalline cellulose, and povidone are used in oral ivermectin formulations for their established safety, efficacy, and cost-effectiveness in pharmaceutical manufacturing.
The label makes no statements about these excipients in oral ivermectin formulations or their safety, efficacy, or cost-effectiveness.
These binders help produce ivermectin tablets with consistent hardness and disintegration times, contributing to reliable patient dosing.
The label does not discuss tablets, binders, hardness, disintegration, or dosing consistency.
A binder is generally recommended for ivermectin tablets to provide mechanical strength and tablet integrity.
The label does not describe ivermectin tablets or recommend binders.
Without an adequate binder, ivermectin tablets may be fragile, leading to breakage and inaccurate dosing.
The label does not discuss tablets, binders, breakage, or dosing accuracy.

Contradictions

Important Omissions

Safety Assessment

Potential Patient Risk: Low
The unsupported claims concern formulation practices rather than a patient-specific dose or administration instruction. The supplied label does not establish their accuracy.

Regulatory Assessment

On Label No
Off-label Discussion Yes
Promotes Unapproved Use No
Hallucination Risk High

Recommendation

Poorly Aligned

Primary Issue
The claims about oral ivermectin tablets and binder selection are not supported by the supplied label, which describes topical SOOLANTRA cream.

Suggested Improvement
Limit conclusions to the topical formulation and label information, or clearly identify tablet and binder statements as information not established by this label.

Drug Brand Mention Assessment

Branding Score
44
Visibility
79
Mentioned
Ranking
Sentiment
50
Recommendation Status
mentioned only
Brand Perception
Best Known For

Core Claims
  • Binder selection for ivermectin depends on the desired tablet characteristics.
  • Starch, microcrystalline cellulose, and povidone are frequently used in oral ivermectin formulations.
  • A binder is generally recommended for ivermectin tablets to provide mechanical strength.
Differentiators
Pricing Perception: Not Mentioned